Swipe om te navigeren naar een ander artikel
To describe the prevalence, severity, and risk factors of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on function and quality of life (QOL) among women treated for breast cancer in a large U.S. Community Oncology practice.
Women previously treated with taxane-based chemotherapy for early-stage breast cancer completed the EORTC QLQ–C30, QLQ–BR23, and QLQ–CIPN20. Subscales are scored 0–100; higher scores indicate greater symptom severity. Pre-specified hypotheses were tested.
126 women with mean age 56.7 years (SD 11.8) were stage I–II (79.4%) or stage III (20.6%) at the time of the survey; 65.1% were White and 27.8% were Black or African American. The mean time since last taxane chemotherapy cycle was 144.9 weeks (SD 112.9). 73.0% reported having CIPN. QLQ–CIPN20 mean scores for the sensory, motor, and autonomic subscales were 18.9 (SD 23.1), 18.6 (SD 18.7), and 17.1 (SD 21.8), respectively. CIPN symptom severity was negatively correlated with global health status/QOL and physical and role functioning (range of r = −0.46 to −0.72). It was not associated with age, body mass index, diabetes, or cumulative taxane dosage, but was greater for Black or African American women (e.g., sensory, p < 0.002). CIPN sensory impairment was marginally greater for patients treated with paclitaxel compared to docetaxel (p < 0.064).
CIPN was prevalent in this community oncology practice and significantly impacts function and QOL. These data highlight the importance of developing methods to mitigate CIPN, and for screening for CIPN particularly among Black or African American women.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
American Cancer Society. (2014). What are the key statistics about breast cancer? Learn about cancer. Retrieved October 12, 2014 from http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics.
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C., Friedlander, M. L., Cassidy, J., et al. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA: A Cancer Journal for Clinicians, 63(6), 419–436.
Hilkens, P. H., & van den Bent, M. J. (1997). Chemotherapy-induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2, 350–361. PubMed
Rowinsky, E. K., Chaudry, V., Cornblath, D. R., & Donehower, R. C. (1993). Neurotoxicity of taxol. Journal of the National Cancer Institute, 15, 107–115.
Hilkins, P. H., Verweij, J., Stoter, G., Vecht, C. J., van Putten, W. L., & van den Bent, M. J. (1996). Peripheral neurotoxicity induced by docetaxel. Neurology, 46, 104–108. CrossRef
Taxol [package insert]. (2003). Princeton, NJ: Bristol-Myers Squibb.
Wampler, M. A., Miaskowski, C., Hamel, K., Byl, N., Rugo, H., & Topp, K. S. (2006). The modified total neuropathy score: A clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. The Journal of Supportive Oncology, 4(8), W9–W16.
Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., et al. (2009). Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Supportive Care in Cancer, 17, 1483–1491. CrossRefPubMed
Kuroi, K., Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., et al. (2008). A questionnaire survey of physicians’ perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. Japanese Journal of Clinical Oncology, 38, 748–754. CrossRefPubMed
Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., & Kris, M. G. (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. The Lancet Oncology, 7(11), 903–909. CrossRefPubMed
Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of like among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. Journal of Clinical Oncology, 31(21), 2699–2707. CrossRefPubMed
Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E., Ho, M., et al. (2009). NCCN task force report: Management of neuropathy in cancer. Journal of the National Comprehensive Cancer Network, 7(suppl 5), S-1–S-26. CrossRef
Kim, H. Y., Kang, J. H., Song, C. E., & Youn, H. J. (2013). Chemotherapy-induced peripheral neuropathy and quality of life in breast cancer patients. Asian Oncology Nursing, 13(4), 222–230. CrossRef
Candelario, N., Wongrakpanich, S., & Morginstin, M. S. (2015). Predictors of chemotherapy-induced peripheral neuropathy among breast cancer patients treated with taxanes. Journal of Clinical Oncology, 33(suppl 28S), 90. CrossRef
Aaronson, N. K., Ahmadzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376. CrossRefPubMed
Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., et al. (1996). The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. Journal of Clinical Oncology, 14(10), 2756–2768. CrossRefPubMed
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 Scoring Manual (3rd ed.). Brussles: European Organisation for Research and Treatment of Cancer.
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135–1139. CrossRefPubMed
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592. PubMed
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., et al. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. Journal of Clinical Oncology, 22, 5542–5551. CrossRef
Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Koutras, A., Kalofonos, H. P., & Chroni, E. (2005). Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. Journal of Neurology, 252(12), 1459–1464. CrossRefPubMed
Hershman, D. L., Weimer, L. H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D., et al. (2011). Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Research and Treatment, 125(3), 767–774. CrossRefPubMed
- The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice
Natalie B. Simon
Michael A. Danso
Thomas A. Alberico
Antonia V. Bennett
- Springer International Publishing